Celgene Shareholders Excited by CAR-T News
At the recent annual American Society of Hematology (ASH) conference, Celgene (NASDAQ: CELG) reported trial results for the multiple myeloma CAR-T drug it's making with bluebird bio (NASDAQ: BLUE), bb2121.
In this clip from Industry Focus: Healthcare, analyst Kristine Harjes and contributor Todd Campbell explain what the drug does and why it's so exciting for patients and investors, how bb2121 is different from its competition, a few things that investors should know about Bluebird Bio before buying in, why this partnership between Celgene and Bluebird is perfect for both companies, and more.
A full transcript follows the video.
Source: Fool.com